AIMS: Missed diagnosis of maturity-onset diabetes of the young (MODY) has led to an interest in biomarkers that enable efficient prioritization of patients for definitive molecular testing. Apolipoprotein M (apoM) was suggested as a biomarker for hepatocyte nuclear factor 1 alpha (HNF1A)-MODY because of its reduced expression in Hnf1a(-/-) mice. However, subsequent human studies examining apoM as a biomarker have yielded conflicting results. We aimed to evaluate apoM as a biomarker for HNF1A-MODY using a highly specific and sensitive ELISA. METHODS: ApoM concentration was measured in subjects with HNF1A-MODY (n = 69), Type 1 diabetes (n = 50), Type 2 diabetes (n = 120) and healthy control subjects (n = 100). The discriminative accuracy of apoM and of the apoM/HDL ratio for diabetes aetiology was evaluated. RESULTS: Mean (standard deviation) serum apoM concentration (μmol/l) was significantly lower for subjects with HNF1A-MODY [0.86 (0.29)], than for those with Type 1 diabetes [1.37 (0.26), P = 3.1 × 10(-18) ) and control subjects [1.34 (0.22), P = 7.2 × 10(-19) ). There was no significant difference in apoM concentration between subjects with HNF1A-MODY and Type 2 diabetes [0.89 (0.28), P = 0.13]. The C-statistic measure of discriminative accuracy for apoM was 0.91 for HNF1A-MODY vs. Type 1 diabetes, indicating high discriminative accuracy. The apoM/HDL ratio was significantly lower in HNF1A-MODY than other study groups. However, this ratio did not perform well in discriminating HNF1A-MODY from either Type 1 diabetes (C-statistic = 0.79) or Type 2 diabetes (C-statistic = 0.68). CONCLUSIONS: We confirm an earlier report that serum apoM levels are lower in HNF1A-MODY than in controls. Serum apoM provides good discrimination between HNF1A-MODY and Type 1 diabetes and warrants further investigation for clinical utility in diabetes diagnostics.
AIMS: Missed diagnosis of maturity-onset diabetes of the young (MODY) has led to an interest in biomarkers that enable efficient prioritization of patients for definitive molecular testing. Apolipoprotein M (apoM) was suggested as a biomarker for hepatocyte nuclear factor 1 alpha (HNF1A)-MODY because of its reduced expression in Hnf1a(-/-) mice. However, subsequent human studies examining apoM as a biomarker have yielded conflicting results. We aimed to evaluate apoM as a biomarker for HNF1A-MODY using a highly specific and sensitive ELISA. METHODS: ApoM concentration was measured in subjects with HNF1A-MODY (n = 69), Type 1 diabetes (n = 50), Type 2 diabetes (n = 120) and healthy control subjects (n = 100). The discriminative accuracy of apoM and of the apoM/HDL ratio for diabetes aetiology was evaluated. RESULTS: Mean (standard deviation) serum apoM concentration (μmol/l) was significantly lower for subjects with HNF1A-MODY [0.86 (0.29)], than for those with Type 1 diabetes [1.37 (0.26), P = 3.1 × 10(-18) ) and control subjects [1.34 (0.22), P = 7.2 × 10(-19) ). There was no significant difference in apoM concentration between subjects with HNF1A-MODY and Type 2 diabetes [0.89 (0.28), P = 0.13]. The C-statistic measure of discriminative accuracy for apoM was 0.91 for HNF1A-MODY vs. Type 1 diabetes, indicating high discriminative accuracy. The apoM/HDL ratio was significantly lower in HNF1A-MODY than other study groups. However, this ratio did not perform well in discriminating HNF1A-MODY from either Type 1 diabetes (C-statistic = 0.79) or Type 2 diabetes (C-statistic = 0.68). CONCLUSIONS: We confirm an earlier report that serum apoM levels are lower in HNF1A-MODY than in controls. Serum apoM provides good discrimination between HNF1A-MODY and Type 1 diabetes and warrants further investigation for clinical utility in diabetes diagnostics.
Authors: Tim J McDonald; Jane McEneny; Ewan R Pearson; Gaya Thanabalasingham; Magdalena Szopa; Beverley M Shields; Sian Ellard; Katharine R Owen; Maciej T Malecki; Andrew T Hattersley; Ian S Young Journal: Clin Chim Acta Date: 2012-02-14 Impact factor: 3.786
Authors: Katharine R Owen; Gaya Thanabalasingham; Timothy J James; Fredrik Karpe; Andrew J Farmer; Mark I McCarthy; Anna L Gloyn Journal: Diabetes Care Date: 2010-08-19 Impact factor: 17.152
Authors: C Cervin; O Axler; J Holmkvist; P Almgren; E Rantala; T Tuomi; L Groop; B Dahlbäck; E Karlsson Journal: J Intern Med Date: 2009-06-22 Impact factor: 8.989
Authors: G Thanabalasingham; N Shah; M Vaxillaire; T Hansen; T Tuomi; D Gašperíková; M Szopa; E Tjora; T J James; P Kokko; F Loiseleur; E Andersson; S Gaget; B Isomaa; N Nowak; H Raeder; J Stanik; P R Njolstad; M T Malecki; I Klimes; L Groop; O Pedersen; P Froguel; M I McCarthy; A L Gloyn; K R Owen Journal: Diabetologia Date: 2011-08-04 Impact factor: 10.122
Authors: Gaya Thanabalasingham; Aparna Pal; Mary P Selwood; Christina Dudley; Karen Fisher; Polly J Bingley; Sian Ellard; Andrew J Farmer; Mark I McCarthy; Katharine R Owen Journal: Diabetes Care Date: 2012-03-19 Impact factor: 19.112
Authors: Christine von Toerne; Michael Laimighofer; Peter Achenbach; Andreas Beyerlein; Tonia de Las Heras Gala; Jan Krumsiek; Fabian J Theis; Anette G Ziegler; Stefanie M Hauck Journal: Diabetologia Date: 2016-11-04 Impact factor: 10.122
Authors: Natalia Nowak; Jerzy Hohendorff; Iwona Solecka; Magdalena Szopa; Jan Skupien; Beata Kiec-Wilk; Wojciech Mlynarski; Maciej T Malecki Journal: Endocrine Date: 2015-05-19 Impact factor: 3.633
Authors: J Hohendorff; M Szopa; J Skupien; M Kapusta; B Zapala; T Platek; S Mrozinska; T Parpan; W Glodzik; A Ludwig-Galezowska; B Kiec-Wilk; T Klupa; M T Malecki Journal: Endocrine Date: 2017-06-07 Impact factor: 3.633